WO2015064975A1 - Compositions comprising a viola herba extract, or an extract of viola herba, persicae semen, cinnamomi ramulus, and glycyrrhiza spp. for the prevention or treatment of lipid-related cardiovascular diseases and obesity - Google Patents

Compositions comprising a viola herba extract, or an extract of viola herba, persicae semen, cinnamomi ramulus, and glycyrrhiza spp. for the prevention or treatment of lipid-related cardiovascular diseases and obesity Download PDF

Info

Publication number
WO2015064975A1
WO2015064975A1 PCT/KR2014/010110 KR2014010110W WO2015064975A1 WO 2015064975 A1 WO2015064975 A1 WO 2015064975A1 KR 2014010110 W KR2014010110 W KR 2014010110W WO 2015064975 A1 WO2015064975 A1 WO 2015064975A1
Authority
WO
WIPO (PCT)
Prior art keywords
viola
extract
herba
persicae semen
cinnamomi ramulus
Prior art date
Application number
PCT/KR2014/010110
Other languages
English (en)
French (fr)
Inventor
Yoon Young Sung
Ho Kyoung Kim
Dong Seon Kim
Go Ya Choi
Original Assignee
Korea Institute Of Oriental Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Institute Of Oriental Medicine filed Critical Korea Institute Of Oriental Medicine
Priority to CN201480071171.1A priority Critical patent/CN105916514A/zh
Priority to EP14858980.7A priority patent/EP3062807A4/en
Publication of WO2015064975A1 publication Critical patent/WO2015064975A1/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/86—Violaceae (Violet family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A61K39/36—Allergens from pollen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Definitions

  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a Viola Herba extract, or an extract of Viola Herba, Persicae Semen, Cinnamomi Ramulus, and Glycyrrhiza spp. for the prevention or treatment of lipid-related cardiovascular diseases or obesity, and a method for prevention of lipid-related cardiovascular diseases or obesity including administering the pharmaceutical composition to a subject in need of the same.
  • the present invention relates to a food additive composition
  • a food additive composition comprising a Viola Herba extract, or an extract of Viola Herba, Persicae Semen, Cinnamomi Ramulus, and Glycyrrhiza spp. for the prevention or improvement of lipid-related cardiovascular diseases or obesity.
  • the number one cause of death was cancers, followed by cerebrovascular diseases, and cardiovascular diseases in this order. It has been known that circulatory diseases such as atherosclerosis, myocardial infarction and stroke are more seriously affected by dietary intake than other chronic diseases.
  • the relevant risk factors known so far include cholesterol level in blood, triglycerides level in blood, hypertension, smoking, thrombosis, diabetes, obesity, etc. Among them, cholesterol level and hypertension are known as the major risk factors causing atherosclerosis and myocardial infarction. Accordingly, the maintenance of the cholesterol concentration in blood to be at a normal level is important to prevent the occurrence of the diseases described above.
  • LDL low-density lipoprotein
  • HDL high-density lipoprotein
  • LDL-cholesterol is known as a risk factor for cardiovascular diseases
  • the increase in triglycerides concentration level is known to decrease the concentration of HDL-cholesterol and increase chylomicron residues, which are mainly composed of triglycerides, thus becoming a major cause of coronary artery diseases.
  • blood lipids can pass through vascular endothelial cells better than other types of lipids and thus can become a major cause of atherosclerosis, and the rapid increase in triglyceride level after a meal is known to be closely related with the occurrence of stroke.
  • HDL-cholesterol can remove cholesterol from vascular walls, and is thus known as a preventive factor of cardiovascular diseases. Accordingly, in order to prevent or treat various diseases occurring due to lipid metabolism disorders, it is important to maintain each of the various components of blood lipids comprised of triglycerides, cholesterol, phospholipids, and free fatty acids at normal levels.
  • diet therapies recommending the intake of dietary fibers, saponins, vitamin C, vitamin D, and essential amino acids are used as a therapeutic method for proper control of the blood lipid components to thereby prevent and treat lipid metabolism disorders.
  • the dietary therapies may not be sustained for a long period because they often accompany a mental discomfort due to limitation in diet.
  • drug therapies have also been used for treating lipid metabolism disorders.
  • the drug therapies for lowering blood lipids level must be maintained over the entire course of life, may cause liver dysfunction, and complications such as myopathy.
  • the drug therapies can no longer be applied. Therefore, there is a growing need for the discovery of a natural substance useful as an active ingredient for the treatment of lipid-related cardiovascular diseases or obesity.
  • Obesity or obesity symptoms are collective terms referring to the medical condition of a person's body weight being excessively high, and from the pathological point of view, it refers to a case when a peron's body mass index (BMI) is 30 or higher according to WHO standards. However, in Korea, a person with a BMI value of 25 or higher is diagnosed as having obesity. In most cases, obesity refers to the physical condition of a person when his or her body weight is higher than normal body weight. However, it may also refer to a state when the lipid content among body constituents is high, although the body weight itself may not be excessive.
  • BMI body mass index
  • Obesity refers to the physical state of a person with excess fat accumulation in the body, which leads to an increase in the number or size of adipocytes in adipose tissues. Obesity may not be a problem in itself, but may become serious when it results in social handicaps induced therefrom and secondary complications due to excessive body fat. For example, obesity may induce major diseases such as hypertension, hyperlipidemia, heat diseases, diabetes atherosclerosis, fatty liver, joint disorders, arthritis, sexual dysfunction, and cancer, and thus has been treated as an important disease. When the body weight of a person increases to 20% over normal body weight, the occurrence rate of diabetes becomes 10 times higher than that for normal people.
  • adipocytes once produced, cannot be naturally removed and remain permanently in the body, although they may be reduced in size. Therefore, it is important to be careful not to become obese. Accordingly, body weight can be reduced primarily by lowering calorie intake while increasing outdoor activities and the amount of exercise.
  • adipocytes are hardly removed once formed, people often take drugs to reduce fat absorption along with a weight-loss dietary intake.
  • these drugs may induce adverse reactions such as cardiovascular disease (e.g., hypertension) and stroke, and once administration of the drug is stopped, body weight often starts to increase.
  • bariatric surgeries may be performed, which may include a surgery to remove body fat, gastroplasty or gastric banding to limit food intake, etc.
  • anti-obesity drugs examples include anorexiants which exert effects by reducing the amount of food intake or regulating body metabolism and increasing exothermic reactions in the body, and is a heat metabolism promoter, a digestive absorption inhibitor, and hormone regulator, etc.
  • anorexiants include adrenergic drugs, serotonergic drugs, and adrenergic-serotonergic drugs, and of them, sales of serotonergic drugs have been prohibited due to the adverse effects of valvular heart disease.
  • Examples of the heat metabolism promoter include an ephedrine-caffeine combination drug and an adipocyte 3 receptor agonist
  • examples of the digestive absorption inhibitor include a lipase inhibitor represented by Xenical, and a low fat food additive called Olestra.
  • the anti-obesity drugs that have been used until now have had numerous reports on their adverse effects including a yo-yo effect, anorexia, headache, blood pressure increase, steatorrhea, diarrhea, pyschonia, etc., which appear to be due to the fact that the products have not been scientifically proven or the effect of reducing body weight with a short period of time has been emphasized. Accordingly, there is a continuing demand for the development of a novel natural substance based on herbal medicines with proven safety having an improved anti-obesity effect with less adverse effects.
  • the present inventors while endeavoring to find a natural substance with the effect of preventing or treating lipid-related cardiovascular diseases or obesity but having less adverse effects, have confirmed that a Viola Herba extract, or an extract of Viola Herba, Persicae Semen, Cinnamomi Ramulus, and Glycyrrhiza spp.
  • lipid-related cardiovascular diseases such as inhibition of body weight increase, inhibition of the amount of dietary intake, and reduction in body fat, and has an effect of treating lipid-related cardiovascular diseases by reducing triglycerides, which is a neutral fat present in blood, reducing LDL-cholesterol, increasing HDL-cholesterol, increasing Adiponectin mRNA expression within adipose tissues, increasing mitochondrial uncoupling protein-2 (UCP-2) mRNA, and reducing blood pressure, thereby completing the present invention.
  • reducing triglycerides which is a neutral fat present in blood
  • reducing LDL-cholesterol increasing HDL-cholesterol
  • Adiponectin mRNA expression within adipose tissues increasing mitochondrial uncoupling protein-2 (UCP-2) mRNA
  • UCP-2 mitochondrial uncoupling protein-2
  • An objective of the present invention is to provide a pharmaceutical composition containing a Viola Herba extract, or an extract of Viola Herba, Persicae Semen, Cinnamomi Ramulus, and Glycyrrhiza spp. for the prevention or treatment of lipid-related cardiovascular diseases or obesity.
  • Another objective of the present invention is to provide a food additive composition comprising a Viola Herba extract, or an extract of Viola Herba, Persicae Semen, Cinnamomi Ramulus, and Glycyrrhiza spp. for the prevention or improvement of lipid-related cardiovascular diseases or obesity.
  • a further objective of the present invention is to provide a method for treatment of lipid-related cardiovascular diseases or prevention of obesity comprising administering the pharmaceutical composition above to a subject in need of the same.
  • Viola Herba extract or the extract of Viola Herba, Persicae Semen, Cinnamomi Ramulus, and Glycyrrhiza spp. of the present invention is effective in reducing body weight, body fat, and total cholesterol in blood, and lowering blood pressure, and thus can be used for effective prevention or treatment of lipid-related cardiovascular diseases or obesity.
  • the Viola Herba extract has been shown to be effective in reducing the occurrence of atherosclerotic lesions; and inhibiting lipid accumulation in liver tissues and in blood, and thus can be effectively used for the prevention or treatment of atherosclerosis.
  • Figure 1 shows a graph illustrating the results of body weight analysis according to the age of the weeks in a normal diet group (normal group) fed with a Viola Herba extract, or an extract of Viola Herba, Persicae Semen, Cinnamomi Ramulus, and Glycyrrhiza spp., a control group with high fat diet (HFD), a group with HFD and xenical, a group with HFD and a Viola Herba extract, a group with HFD and an extract of Persicae Semen, Cinnamomi Ramulus, and Glycyrrhiza spp., and a group with HFD and an extract of Viola Herba, Persicae Semen, Cinnamomi Ramulus, and Glycyrrhiza spp.
  • HFD high fat diet
  • Figure 2 shows a graph illustrating the adiponectin mRNA expression in adipose tissues of a control group and in each of the experimental groups of the present invention.
  • Figure 3 shows a graph illustrating the UCP-2 mRNA expression in adipose tissues of the control group and in each of the experimental groups of the present invention.
  • Figure 4 shows a graph illustrating the blood pressure measured in the control group and in each of the experimental groups of the present invention.
  • Figure 5 shows a graph illustrating the inhibitory effect of a Viola Herba extract on increases in body weight in an atherosclerotic mouse model.
  • Figure 6 shows a graph illustrating the effect of a Viola Herba extract capable of reducing the size of fat cells in liver tissues and the fat deposition in an atherosclerotic mouse model.
  • Figure 7 shows pictures illustrating the inhibitory effect of a Viola Herba extract on increases in liver weight in an atherosclerotic mouse model.
  • Figure 8 is a graph illustrating the effect of a Viola Herba extract capable of reducing the occurrence of atherosclerotic lesions in an atherosclerotic mouse model (A: pictures of sections of arterial tissue with dyed fats, B: a graph with measured atherosclerotic lesions).
  • Figure 9 is a graph illustrating the effect of a Viola Herba extract capable of increasing AMPK activity; and inhibiting expression of Fatty Acid Synthase (FAS) and Sterol Regulatory Element-Binding Protein-1 (SREBP-1) proteins.
  • FAS Fatty Acid Synthase
  • SREBP-1 Sterol Regulatory Element-Binding Protein-1
  • the present invention provides a pharmaceutical composition containing a Viola Herba extract, or an extract of Viola Herba, Persicae Semen, Cinnamomi Ramulus, and Glycyrrhiza spp. for the prevention or treatment of lipid-related cardiovascular diseases or obesity.
  • the present inventors while performing studies on various natural substances with a view to find a natural substance capable of preventing or treating lipid-related cardiovascular diseases or obesity with less adverse effects, have discovered the effects of a Viola Herba extract, or an extract of Viola Herba, Persicae Semen, Cinnamomi Ramulus, and Glycyrrhiza spp..
  • the present inventors extracted Viola Herba or a mixture of Viola Herba, Persicae Semen, Cinnamomi Ramulus, and Glycyrrhiza spp. with water, and thereby obtained a Viola Herba extract, or an extract of Viola Herba, Persicae Semen, Cinnamomi Ramulus, and Glycyrrhiza spp.. They conducted an experiment on the Viola Herba extract, and the extract of Viola Herba, Persicae Semen, Cinnamomi Ramulus, and Glycyrrhiza spp.
  • Viola Herba extract, and the extract of Viola Herba, Persicae Semen, Cinnamomi Ramulus, and Glycyrrhiza spp. have the effects of inhibiting body weight increase, inhibiting the amount of dietary intake, and reducing body fat, and also reducing triglycerides, which is a neutral fat in blood, reducing LDL-cholesterol, increasing HDL-cholesterol, increasing Adiponectin mRNA expression within adipose tissues, increasing UCP-2 mRNA expression, and reducing blood pressure.
  • Viola Herba extract to examine its effect on the prevention or treatment of atherosclerosis using an Apolipoprotein E (ApoE) gene-deleted mouse model with atherosclerosis, and confirmed that the Viola Herba extract has the effects of inhibiting body weight increase; inhibiting the liver weight increase and reducing fat deposition; reducing the occurrence of atherosclerotic lesions; reducing the levels of total cholesterol, LDL-cholesterol, triglycerides and glucose; increasing AMPK activity; and inhibiting the expression of FAS and SREBP-1 proteins.
  • Apolipoprotein E Apolipoprotein E
  • Viola Herba extract and the extract of Viola Herba, Persicae Semen, Cinnamomi Ramulus, and Glycyrrhiza spp. can be used for the prevention, treatment or improvement of lipid-related cardiovascular diseases or obesity.
  • lipid-related cardiovascular diseases may collectively refer to circulatory vascular diseases, heart diseases, cerebrovascular diseases, etc., specifically at least one selected from the group consisting of atherosclerosis, hypertension, myocardial infarction, stroke, hyperlipidemia, ischemic heart disease, cardiac arrhythmia, heart failure, angina pectoris, endocarditis, cardiac valve disorder, conduction disorder, and ischemic cerebrovascular disease, but is not limited thereto.
  • circulatory vascular diseases collectively refers to diseases occurring in various organs including heart involved in the systemic circulation and others associated with pulmonary circulation.
  • heart diseases collectively refers to diseases related to the heart in charge of blood supply for the human body, including ischemic heart diseases, cardiac arrhythmia, heart failure, etc.
  • ischemic heart diseases may include angina pectoris, myocardial infarction, etc., and they refer to acute or chronic heart disorders occurring due to the decrease or blocking of blood flow to cardiac muscle along with the progress of coronary artery disease.
  • Other heart diseases include endocarditis, cardiac valve disorder, conduction disorder, cardiac arrhythmia, heart failure, etc.
  • heart failure refers to a state where the heart cannot sufficiently pump out blood being returned to the heart through a venous system.
  • cerebrovascular disease refers to a disease that makes people collapse due to sudden brain dysfunction caused by problems with the blood vessels in the brain, which, depending on the type of occurrence, can be subdivided into hemorrhagic cerebrovascular disease due to intracranial hemorrhage with partial rupture of blood vessels and ischemic cerebrovascular disease due to blockage or insufficient blood flow in the blood vessels of the brain, but is not limited thereto.
  • the term "obesity” refers to a medical condition wherein there is an excess of body fat, and from a clinical point of view, it refers to a state with BDI of 25 or higher in Korea, and 30 or higher according to WHO standards. Obesity generally refers to a person's physical body state when his or her body weight exceeds the average body weight, however, it may also refer to a person's physical state when the lipid content among body constituents is relatively high although the body itself may not be excessively overweight. Obesity is a disease occurring in both adults and children.
  • anti-obesity is a term that is inclusive of prevention, treatment, and improvement of obesity. Accordingly, the term “anti-obesity composition”, as used herein, refers to a pharmaceutical composition for the prevention or treatment of obesity as defined above.
  • Viola Herba refers to the entire plant of Viola mandshurica belonging to Violaceae family or Viola yezoensis belonging to Violaceae family.
  • Viola Herba has a particular smell, is pungent, and tastes bitter and spicy. Additionally, it has the efficacies of fever alleviation and detoxification. It contains saponin, flavonoid compounds, cerotic acid, unsaturated fatty acids, etc.
  • saponin, flavonoid compounds, cerotic acid, unsaturated fatty acids, etc have not been identified yet.
  • Persicae Semen refers to seeds (breed) or seeds and branches of Prunus persica or Prunus davidiana belonging to Rosaceaas family. It has almost no smell, is oily, tastes bitter and sweet, and constantly retains the same property without being sided. Since Persicae Semen can remove extravasated blood it can be used for treating abdominal pains, blocked menstruation, dysmenorrhea, contusions, lung abscess, appendicitis, etc. Due to high fat content, it can lubricate intestines and is thus effective for treatment of constipation, and is also useful for the treatment of skin irritation due to blood heat; dry skin; freckles, etc. Its branches can alleviate sudden deep abdominal pain.
  • Cinnamomi Ramulus refers to branches of bark of a tree belonging to Cinnamomum sp . In detail, it may be a branch or bark of Cinnamomum cassia or Cinnamomum lourestory belonging to Cinnamomum sp ., but is not limited thereto. Its pharmacological actions include inhibition of growth of E. coli , Bacillus substilis, Staphylococcus aureus, Streptococcus pneumonia , etc., inhibition of influenza virus, diuretic action, etc.
  • Glycyrrhiza spp. refers to a perennial plant belonging to Glycyrrhiza .
  • Glycyrrhiza spp. can be Glycyrrhiza glabra , Glycyrrhiza uralensis , Glycyrrhiza inflata , Glycyrrhiza pallidiflora , Glycyrrhiza squamulosa , or Glycyrrhiza echinata , but is not limited thereto.
  • Glycyrrhiza spp. may be used with its roots or stems attached or after peeling them off.
  • extract refers to a liquid extract of medicinal herbs obtained using an extraction solvent, although not limited thereto, and may refer to a liquid extract obtained by extraction, a diluent or concentrate of the liquid extract, a dried product obtained by drying the liquid extract, a coarse purified product or purified product obtained therefrom.
  • the extract may be obtained by extraction using an extraction solvent, or by fractionation by adding a fractionation solvent to an extract obtained by extraction using an extraction solvent.
  • the extraction solvent may not be limited but water, an organic solvent, or a mixed solvent thereof may be used.
  • the organic solvent may be C 1-4 alcohol, a polar solvent such as ethyl acetate or acetone, a nonpolar solvent such as hexane or dichloromethane, or a mixed solvent thereof.
  • water, C 1-4 alcohol, or a mixed solvent thereof may be used.
  • the extract was obtained using water as the extraction solvent.
  • an extract of Viola Herba, Persicae Semen, Cinnamomi Ramulus, and Glycyrrhiza spp refers to an extract obtained by extracting a combined mixture comprising Viola Herba, and a mixture of Persicae Semen, Cinnamomi Ramulus, and Glycyrrhiza spp. at a weight ratio of 1:1 to 1:5.
  • the weight ratio is in the range of 1:2 to 1:4, more preferably 1:3, but is not limited thereto.
  • the mixture of Persicae Semen, Cinnamomi Ramulus, and Glycyrrhiza spp. may be mixed at a weight ratio of 1:1:1 to 6:2:1, specifically, in a weight ratio of 3:2:2, but is not limited thereto.
  • the Viola Herba extract or the extract of the combined mixture comprising Viola Herba and the mixture of Persicae Semen, Cinnamomi Ramulus, and Glycyrrhiza spp. may be prepared by a conventional extraction method, and separation and purification methods known in the art.
  • Examples of the extraction method although not limited thereto, may include hot-bath extraction, hot-water extraction, macerating, reflux extraction, sonication extraction, etc.
  • the Viola Herba extract or the extract of Viola Herba, Persicae Semen, Cinnamomi Ramulus, and Glycyrrhiza spp. was obtained by extracting the entire plant for Viola Herba, the seeds of Persicae tree for Persicae Semen, barks of Cinnamomum cassia or Cinnamomum lourestory for Cinnamomi Ramulus, and the entire plant exclusive of bark for Glycyrrhiza spp., but other parts may be used as well.
  • the Viola Herba extract of the present invention was obtained by adding 5 to 20 volumes of an extraction solvent to the dry weight of Viola Herba.
  • the extract of a mixture of Persicae Semen, Cinnamomi Ramulus, and Glycyrrhiza spp. was obtained by extracting the mixture of the dried Persicae Semen, Cinnamomi Ramulus, and Glycyrrhiza spp. in a mixing ratio of 3:2:2 via hot-water extraction.
  • Example 2 the administration of the Viola Herba extract of the present invention to a high fat diet group was shown to reduce the body weight of mice starting from 11 weeks of age, compared to those in the high fat diet group without treatment, whereas the administration of the extract of Viola Herba, Persicae Semen, Cinnamomi Ramulus, and Glycyrrhiza spp. was shown to more significantly reduce the body weight of mice compared to when the Viola Herba extract was administered alone ( Figure 1 and Table 1).
  • the Viola Herba extract was shown to be effective in reducing body weight and inhibiting the amount of dietary intake, and the extract of Viola Herba, Persicae Semen, Cinnamomi Ramulus, and Glycyrrhiza spp. was shown to more significantly reduce body weight and inhibit the amount of dietary intake (Table 2).
  • Example 4 the effects of the Viola Herba extract or the extract of Viola Herba, Persicae Semen, Cinnamomi Ramulus, and Glycyrrhiza spp. on blood lipids were examined, and it was confirmed that the administration of the Viola Herba extract or the extract of Persicae Semen, Cinnamomi Ramulus, and Glycyrrhiza spp. reduced the levels of total cholesterol and LDL-cholesterol while increasing the level of HDL-cholesterol.
  • the administration of the extract of Viola Herba, Persicae Semen, Cinnamomi Ramulus, and Glycyrrhiza spp. was shown to reduce the concentrations of blood glucose, total cholesterol, triglycerides, LDL-cholesterol while increasing the concentration of HDL-cholesterol (Table 3).
  • Example 5 the administration of the extract of Persicae Semen, Cinnamomi Ramulus, and Glycyrrhiza spp. on a high fat diet group was shown to significantly increase the expression of Adiponectin mRNA involved in glucose metabolism and lipid decomposition, and the administration of the extract of Viola Herba, Persicae Semen, Cinnamomi Ramulus, and Glycyrrhiza spp. on a high fat diet group was also shown to increase the expression of Adiponectin mRNA (Figure 2).
  • an ApoE gene-deleted mouse model with atherosclerosis was administered with a Viola Herba extract while being fed with high fat diet. Additionally, the control group was fed with general feed and the positive control group was administered with atovastatin (Example 7-1).
  • the adminsitration with the Viola Herba extract is effective on inhibiting body weight increase; inhibiting liver weight; reducing the size of adipocytes and the fat deposition in liver tissues; reducing the incidence of atherosclerotic lesions; lowering the concentrations of total cholesterol, LDL-cholesterol, triglycerides and glucose; increasing AMPK activity; and inhibiting the expression of FAS and SREBP-1 proteins (Examples 7-2 through 7-7).
  • prevention refers to all kinds of activities that inhibit or delay the occurrence of lipid-related cardiovascular diseases or obesity by administering a pharmaceutical composition according to the present invention
  • treatment refers to all kinds of activities that improve or advantageously change the symptoms of a subject with lipid-related cardiovascular diseases or obesity or a subject suspected of having the same by administering the pharmaceutical composition.
  • the pharmaceutical composition of the present invention may further include a pharmaceutically acceptable carrier.
  • a pharmaceutically acceptable carrier refers to the characteristics of being non-toxic to cells or humans being exposed to the composition.
  • the above carrier may be anything known in the art such as a buffering agent, a preservative, a pain-relieving agent, a solubilizer, an isotonic agent, a stabilizer, an excipient, a lubricant, etc.
  • the pharmaceutical compositoin of the present invention may be formulated into preparations for oral administration such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, etc., external preparations, suppositories, and sterile injections. Furthermore, it may be used in the form of an external preparation for skin such as ointments, lotions, sprays, patches, cream, powders, suspensions, gels or dermatologic drugs.
  • the carriers, excipients, and diluents that can be included in the compositon of the present invention are: lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil, etc.
  • commonly used fillers, extenders, binders, humectants, disintegrating agents, diluents such as surfactants or excipients may be used.
  • Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc.
  • the above solid preparations may be prepared by adding at least one excipient, e.g., starch, calcium carbonate, sucrose, lactose, gelatin, etc., to the Viola Herba extract or the extract of Viola Herba, Persicae Semen, Cinnamomi Ramulus, and Glycyrrhiza spp.
  • lubricants such as magnesium stearate, talc, etc., may be used in addition to the simple excipients.
  • liquid preparations for oral administration include suspensions, preparations for internal use, emulsifiers, syrups, etc., and various kinds of excipients, e.g., humectants, sweeteners, fragrants, preservatives, etc., may be used in addition to simple diluents such as water and liquid paraffin.
  • Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsifiers, lyophilized preparations, and suppositories.
  • non-aqueous solvents or suspensions include propylene glycol, polyethylene glycol, a vegetable oil such as olive oil, an injectable ester such as ethylolate, etc.
  • suppository bases include Macrogol, Tween 61, cacao butter, laurinum, glycerogelatin, etc.
  • the amount of the Viola Herba extract or the extract of Viola Herba, Persicae Semen, Cinnamomi Ramulus, and Glycyrrhiza spp . may not be particularly limited, but is preferably contained in the amount of 0.01 to 100 wt%, and more preferably 1 to 100 wt%, relative to the total weight of the final composition.
  • the pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount.
  • administration refers to the introduction of a particular substance into a subject by an appropriate method, and the administration route of the composition may be any conventional route that enables delivery of the composition to the target tissue, for exmaple, intraperitoneal adminstration, intravenous administration, intramuscular administration, subcutaneous administration, intradermal adminsitration, oral administration, local administration, intransal adminstration, intrapulmonary administration, and intrarectal administration, but is not limited thereto.
  • the term "subject” refers to all kinds of animals such as rats, mice, livestock and humans, preferably mammals including humans, which already have the lipid-related cardiovascular disease(s) or obesity or have the potential of having the same.
  • a pharmaceutically effective amount refers to an amount sufficient for the treatment of a disease at a reasonable benefit/risk ratio but without any adverse effects, thereby being applicable to medical treatment, and the level of the effective dosage may be easily determined by a skilled person in the art in consideration of sex, age, body weight, health status of a subject, type of a disease, severity of a disease, drug activities, drug sensitivities, methods of administration, duration of adminstration, drug efflux rate, duration of treatment, combination of drugs or factors including drugs used in combination, and other factors well known in the medical field.
  • the pharmaceutical composition comprising a Viola Herba extract, or an extract of Viola Herba, Persicae Semen, Cinnamomi Ramulus, and Glycyrrhiza spp. of the present invention may be administered daily in the amount of 0.0001 to 1000 mg/kg of body weight, more preferably 0.001 to 500 mg/kg of body weight.
  • the administration may be performed once daily or in divided doses per day.
  • Viola Herba extract or the extract of Viola Herba, Persicae Semen, Cinnamomi Ramulus, and Glycyrrhiza spp. of the present invention is prepared using natural herb materials it will have much fewer adverse effects than the genenral synthetic compounds and thus can be used safely.
  • a food additive composition for the prevention or improvement of lipid-related cardiovascular diseases or obesity containing the Viola Herba extract or the extract of Viola Herba, Persicae Semen, Cinnamomi Ramulus, and Glycyrrhiza spp. as an active ingredient.
  • the tersms of Viola Herba, Persicae Semen, Cinnamomi Ramulus, Glycyrrhiza spp ., extract, lipid-related cardiovascular diseases, obesity, and prevention are the same as defined above.
  • the term “improvement” refers to all kinds of activities that can improve or advantageously change the symptoms of lipid-related cardiovascular diseases or obesity by administering the above composition.
  • the term "food additive composition” means a composition intended to be added to any food for providing desired effects.
  • Viola Herba extract or the extract of Viola Herba, Persicae Semen, Cinnamomi Ramulus, and Glycyrrhiza spp. of the present invention is not only shown to be effective in the prevention or treatment of lipid-related cardiovascular diseases or obesity but also has been shown to be safe because it is derived from natural substances. Accordingly, they can be used in a food additive composition to manufacture a health functional food for the prevention or improvement of obesity.
  • the Viola Herba extract or the extract of Viola Herba, Persicae Semen, Cinnamomi Ramulus, and Glycyrrhiza spp. may be directly used by adding them or may be used in combination with other foods or food components, and may be appropriately used according to a conventional method.
  • the amount of active ingredients may be appropriately determined according to their intended use (prevention, health or therapeutic treatment), and auxiliary food additive(s) acceptable from the food nutritional point of view may be further added thereto. Since the Viola Herba extract or the extract of Viola Herba, Persicae Semen, Cinnamomi Ramulus, and Glycyrrhiza spp.
  • the amount to be added into the food additive composition may not be particularly limited, but is preferably in the range of 0.001 to 100 wt%, more preferably 0.01 to 80 wt% relative to the weight of the total composition.
  • the composition may further include other components that are conventionally used in food compositions to improve smell, taste, visual flavor, etc., for example, vitamins A, C, D, E, B1, B2, B6, B12, niacin, biotin, folate, panthotenic acid, etc.
  • minerals such as Zn, Fe, Ca, Cr, Mg, Mn, and Cu may be included.
  • amino acids such as lysine, tryptophane, cysteine, and valine may be included.
  • food additives such as a preservative (potassium sorbate, sodium benzoate, salicylic acid, sodium dehydroacetate, etc.), a germicide (bleaching powder and high-grade bleaching powder, sodium hypochlorite, etc.), an antioxidant (butylhydroxyanisole (BHA), butylhydroxytoluene (BHT), etc.), a coloring agent (tar color, etc.), a color fixing agent (sodium nitrite, etc.), a bleaching agent (sodium sulfite), a seasoning (MSG, sodium glutamate, etc.), a sweetenre (dulcin, cyclamate, saccharin, sodium, etc.), a flavor (vanillin, lactones, etc.), a swelling agent (alum, D-potassium bitartate, etc.), a reinforcing agent, an emulsifier,
  • the food additive composition of the present invention being an additive added during the manufacture of conventional foods, may be used in the manufacture of foods effective in prevention or improvement of lipid-related cardiovascular diseases or obesity.
  • the foods having the food additive composition may be interchangeably used with terms such as functional foods, health functional foods, etc., well known in the art.
  • the term “functions foods” refers to foods manufactured or processed using material(s) or component(s) with useful functions according to the Korean Law No. 6727 for health functional foods, and as used herein, the term “functional” refers to the activity of an intake for the purpose of obtaining useful effects on health-related uses such as regulating nutrients or physiological actions regarding the structure and functions of human body.
  • health functional foods refers to foods manufactured or processed via extraction, concentration, purification, mixing, etc., of particular components as raw materials or particular components contained in the food materials for the purpose of health supplement, and the foods designed and processed to sufficiently exhibit the biological regulatory functions such as biological defense and biological rhythm, prevention and recovery of diseases, etc., to a living subject by the above components.
  • the food types in which the composition of the present invention can be added thereto may include all kinds of foods such as special nutritious foods (e.g., milk formula, infant formula, etc.), processed meat products, fish meat products, soybean curd, starch jelly, noodles (e.g., ramens, fine noodles, etc.), health supplementary foods, seasoning foods (e.g., soy sauce, soybean paste, red pepper paste, mixed soybean paste, etc.), sauces, confectioneries (e.g., snacks), dairy products (e.g., fermented milk, cheese, etc.), other processed foods, kimchi, pickled foods (various kimchies, pickled vegetables, etc.), beverages (e.g., fruits, vegetable drinks, soybean milk, fermented drinks, etc.), natural seasonings (e.g., ramen soup, etc.), etc.
  • special nutritious foods e.g., milk formula, infant formula, etc.
  • processed meat products e.g., fish meat products, soybean curd, starch jelly, noodles (e
  • lipid-related cardiovascular diseases or obesity including administering the above pharmaceutical composition to a subject in need of the same.
  • Viola Herba was purchased from Omniherb Co.(Daegu, KOREA), and extracted via hot-water extraction by adding 10 volumes of water.
  • Persicae Semen, Cinnamomi Ramulus, and Glycyrrhiza spp. were purchased from Kwangmyungdang Medicinal Herbs (Ulsan, KOREA).
  • the dried herb materials were mixed at a weight ratio of 3:2;2 between Persicae Semen, Cinnamomi Ramulus, and Glycyrrhiza spp., and extracted via hot-water extraction.
  • Example 1 Construction of a high fat diet (HFD)-inducing animal model
  • mice Male C57bl/6 mice were used after purchasing them from the Jackson Laboratory (Bar Harbor, Maine, USA). Of them, healthy 10 week-old mice were subjected to a maintenance experiment under Specific Pathogenic Free (SPF) condition, and allowed to freely intake foods and water.
  • SPF Pathogenic Free
  • a high fat diet (HFD) Rodent diet D12492, Research Diets, New Brunswick, NJ, USA) consisting of proteins (20%), carbohydrates (20%), and fats (60%) was used after purchasing it from Central Lab. Animal Inc. (Seoul, KOREA).
  • the experimental animals were adapted to basic feeds (AIN-76A diet) for 2 weeks, and then co-administered with HFD diet and herb drugs from 8 weeks of age for 7 weeks.
  • the experimental groups were a total of 6 consisting of: a normal group (Normal Diet) administered with saline while being fed with general feeds, a control group (HFD) administered with saline while being fed with HFD, a positive control group (15.6 mg/kg) administered xenical while being fed with HFD, and 3 groups administered with drug (200 mg/kg) while being fed with HFD. All test materials were suspended in saline and orally administered at the same time dailly using a mouse sonde.
  • Example 2 Effects of a Viola Herba extract, or an extract of Viola Herba, Persicae Semen, Cinnamomi Ramulus, and Glycyrrhiza spp. on reducing body weight and inhibition of food intakes
  • the body weight and the amount of feed intake of the experimental animals were measured using an electronic scale (GP5202, Sartorius, Germany), analyzed, and the feed efficiency ratio (EFR) was calculated based on the ratio of the body weight gain over the amount of feed intake.
  • EFR feed efficiency ratio
  • the HFD group administered with a Viola Herba extract showed a decrease in their body weight starting from the age of 11 weeks compared to that of the HFD-control group.
  • the HFD group administered with an extract of Viola Herba, Persicae Semen, Cinnamomi Ramulus, and Glycyrrhiza spp. (HFD-Viola Herba + (Persicae Semen, Cinnamomi Ramulus, Glycyrrhiza spp.)) showed a significant decrease in their body weight gain compared to that administered with the Viola Herba extract alone (p ⁇ 0.05)( Figure 1).
  • Table 1 Group Feed intakes (g/day) Body weight gain (g/day) Feed efficiency ratio (FER,%) Normal Diet 3.52 0.161 ⁇ 0.01 4.57 ⁇ 0.30 HFD (HFD-control group) 3.14 0.441 ⁇ 0.03 ### 14.06 ⁇ 0.83 ### HFD-xenical 2.86 0.230 ⁇ 0.01 *** 8.04 ⁇ 0.37 *** HFD-Viola Herba 2.89 0.239 ⁇ 0.01 *** 8.27 ⁇ 0.49 *** HFD-Persicae Semen, Cinnamomi Ramulus, Glycyrrhiza spp.
  • the body weight gain in the HFD group was significant compared to that of Normal Diet group (normal group), and the HFD group administered with the Viola Herba extract (HFD-Viola Herba) showed a significant decrease in the body weight gain (p ⁇ 0.05). Additionally, the HFD group administered with the extract of Viola Herba, Persicae Semen, Cinnamomi Ramulus, and Glycyrrhiza spp. (HFD-Viola Herba + (Persicae Semen, Cinnamomi Ramulus, Glycyrrhiza spp.)) showed a significant decrease in the body weight gain.
  • HFD-Viola Herba the HFD group administered with the Viola Herba extract
  • HFD-Viola Herba + the HFD group administered with the extract of Viola Herba, Persicae Semen, Cinnamomi Ramulus, and Glycyrrhiza spp.
  • the FER showed a more significant decrease in the FER (p ⁇ 0.05)(Table 1).
  • Viola Herba extract is effective in reducing body weight and inhibiting the amount of dietary intake
  • the extract of Viola Herba, Persicae Semen, Cinnamomi Ramulus, and Glycyrrhiza spp. is more effective than the Viola Herba extract in reducing body weight and inhibiting the amount of dietary intake.
  • Example 3 Effect of a Viola Herba extract, or an extract of Viola Herba, Persicae Semen, Cinnamomi Ramulus, Glycyrrhiza spp. on reducing body fat weight
  • Example 2 Upon analysis of the result of Example 1, the mice were sacrificed and the amount of their abdominal fat was compared. As a result, as can be seen in Table 2, the HFD group (HFD-control group) showed an increase in the weight of Subcutaneous fat, fat tissues around epididymis, and liver tissues. The group administered with the Viola Herba extract (HFD-Viola Herba) showed a significant decrease in the weight of Subcutaneous fat, intestinal fat tissues, and liver tissues.
  • HFD-Viola Herba + Persicae Semen, Cinnamomi Ramulus, Glycyrrhiza spp.
  • Example 4 Effect of a Viola Herba extract, or an extract of Viola Herba, Persicae Semen, Cinnamomi Ramulus, and Glycyrrhiza spp. on lipid in blood
  • mice Blood samples collected from mice were left at room temperature for 30 minutes, and centrifuged at 3000 rpm for 15 minutes to obtain blood sera. The contents of glucose, total cholesterol, triglycerides, LDL, and HDL in blood sera were measured and analyzed via blood biochemical analyzer (Table 3).
  • HFD-control group HFD-control group
  • triglycerides in blood than the Normal Diet group (normal group)
  • HFD group administered with the Viola Herba extract or the extract of Persicae Semen, Cinnamomi Ramulus, and Glycyrrhiza spp. showed a decrease in the concentrations of total cholesterol and LDL-cholesterol while showing an increase in the concentration of HDL-cholesterol (p ⁇ 0.05).
  • the concentrations of glucose, total cholesterol, triglycerides, and LDL-cholesterol, and triglycerides were significantly decreased while the concentration of HDL-cholesterol was increased (p ⁇ 0.05).
  • Example 5 Effects of a Viola Herba extract or an extract of Viola Herba, Persicae Semen, Cinnamomi Ramulus, and Glycyrrhiza spp. on increase of the expression of Adiponectin and Mitochondrial Uncoupling Protein-2 (UCP-2) genes
  • the HFD group administered with the Viola Herba extract (HFD-Viola Herba) or the extract of Persicae Semen, Cinnamomi Ramulus, and Glycyrrhiza spp. showed an increase in mRNA expression of UCP-2
  • the HFD group administered with the extract of Viola Herba, Persicae Semen, Cinnamomi Ramulus, and Glycyrrhiza spp. also showed a significant increase in mRNA expression of UCP-2 (Figure 3).
  • Example 6 Effect of a Viola Herba extract and an extract of Viola Herba, Persicae Semen, Cinnamomi Ramulus, Glycyrrhiza spp. on reduction of blood pressure
  • Example 7-1 Construction of an animal model with HFD-induced atherosclerosis
  • mice As experimental model animals with atherosclerosis, 6 week-old ApoE gene-deleted mice were provided by Jackson Laboratory (Bar Harbor, Maine, USA) and allowed to adapt for 2 weeks while being freely supplied with a basic feed (AIN-76A diet) and water. Upon their adaptation, HFD feeds were used after purchasing from Central Lab. Animal Inc. (Seoul, Korea), and the feeds contained 45% of fats and 0.15% of cholesterol.
  • the experimental animals were subjected to a combined administration of both HFD and drugs for 16 weeks starting from the 8 weeks of age.
  • the experimental groups were a total of 4 consisting of: a normal group administered with saline while being fed with general feeds, a HFD group administered with saline while being fed with HFD, a drug-treated group (v. mandshurica, 150 mg/kg) administered with a drug while being fed with HFD, and a positive control group administered with atovastatin as a drug while being fed with HFD. All test materials were suspended in saline and administered orally on the same predetermined time daily via a mouse sonde.
  • Example 7-2 Effect of a Viola Herba extract on inhibition of body weight gain
  • Example 7-3 Effect of a Viola Herba extract on inhibition of liver weight gain
  • mice administered with a Viola Herba extract for 16 weeks were autopsied, and the liver tissues obtained therefrom were measured for their weight.
  • the HFD group showed an increase in liver weight compared to the control group, but the liver weight of the drug-treated group administered with a Viola Herba ( V. mandshurica ) extract, although fed with HFD, was similar to that of the normal group which was fed with general feeds (p ⁇ 0.05) ( Figure 6). Accordingly, it was confirmed that the Viola Herba extract is effective in inhibiting the liver weight gain.
  • Example 7-4 Effect of a Viola Herba extract on inhibition of lipid deposition on liver tissues
  • Example 7-5 Effect of a Viola Herba extract on improvement of blood lipids
  • Example 7-6 Effect of a Viola Herba extract on improvement of blood lipids
  • mice Blood samples collected from mice were left at room temperature for 30 minutes, centrifuged at 3000 rpm for 15 minutes to obtain blood sera. The contents of glucose, total cholesterol, triglycerides, LDL, and HDL in the blood sera were measured via blood biochemical analyzer (Table 4).
  • Example 7-7 Effect of a Viola Herba extract on inhibition of factors involved in lipid synthesis in liver tissues
  • AMPK AMP-activated protein kinase
  • Fatty Acid Synthase Fatty Acid Synthase
  • SREBP-1 Sterol Regulatory Element-Binding Protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Medicines Containing Plant Substances (AREA)
PCT/KR2014/010110 2013-10-28 2014-10-27 Compositions comprising a viola herba extract, or an extract of viola herba, persicae semen, cinnamomi ramulus, and glycyrrhiza spp. for the prevention or treatment of lipid-related cardiovascular diseases and obesity WO2015064975A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201480071171.1A CN105916514A (zh) 2013-10-28 2014-10-27 用于预防或治疗脂质相关的心血管疾病和肥胖的包含紫花地丁提取物,或紫花地丁、桃仁、桂枝和甘草属的提取物的组合物
EP14858980.7A EP3062807A4 (en) 2013-10-28 2014-10-27 Compositions comprising a viola herba extract, or an extract of viola herba, persicae semen, cinnamomi ramulus, and glycyrrhiza spp. for the prevention or treatment of lipid-related cardiovascular diseases and obesity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2013-0128791 2013-10-28
KR20130128791 2013-10-28

Publications (1)

Publication Number Publication Date
WO2015064975A1 true WO2015064975A1 (en) 2015-05-07

Family

ID=53004509

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2014/010110 WO2015064975A1 (en) 2013-10-28 2014-10-27 Compositions comprising a viola herba extract, or an extract of viola herba, persicae semen, cinnamomi ramulus, and glycyrrhiza spp. for the prevention or treatment of lipid-related cardiovascular diseases and obesity

Country Status (4)

Country Link
EP (1) EP3062807A4 (zh)
KR (1) KR101672274B1 (zh)
CN (1) CN105916514A (zh)
WO (1) WO2015064975A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102130044B1 (ko) * 2018-03-23 2020-07-03 한국한의학연구원 천연 혼합 추출물을 포함하는 비만 예방 또는 치료용 조성물
CN112386655A (zh) * 2019-08-14 2021-02-23 百岳特生物技术（上海）有限公司 大白蝴蝶兰萃取物用于制备抗醣化与改善皮肤外观的组合物的用途
CN113209196A (zh) * 2021-03-16 2021-08-06 宁夏医科大学 一种与动脉粥样硬化斑块稳定性相关的中药组合物及应用
CN112891438A (zh) * 2021-03-16 2021-06-04 宁夏医科大学 一种用于动脉粥样硬化预防、治疗的中药组合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002032438A1 (fr) * 2000-09-13 2002-04-25 Jiangsu Kanion Pharmaceutical Co. Composition pharmaceutique traitant les maladies gynecologiques associees a la stase sanguine, les maladies cardio-vasculaires et cerebrales, les maladies respiratoires et autres maladies analogues
EP2491934A1 (en) * 2009-10-20 2012-08-29 Zuoguang Zhang Use of albiflorin for anti-depression

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1122243A (zh) * 1995-08-16 1996-05-15 岳泰出 消栓通脉散
JP5609834B2 (ja) * 2004-04-09 2014-10-22 大正製薬株式会社 リパーゼ阻害剤
JP4929611B2 (ja) * 2004-04-09 2012-05-09 大正製薬株式会社 リパーゼ阻害剤
US20060099282A1 (en) * 2004-11-10 2006-05-11 Kazuoki Ishihara Product of coromandel and method for its use
HUP0500813A2 (en) * 2005-09-01 2008-02-28 Elsoe Magyar Biodrog Kutato Es Pharmaceutical composition containing violaceae extract
KR101007088B1 (ko) * 2005-12-30 2011-01-10 (주)아모레퍼시픽 생약 및 자생식물 추출물을 함유하는 지방산 산화 촉진용조성물
KR20080050794A (ko) * 2006-12-04 2008-06-10 장용훈 복합 생약 추출물(ｍｓｔ)을 함유하는 비만의 예방 및치료용 조성물
CN101601780A (zh) * 2008-06-10 2009-12-16 中国医学科学院药物研究所 植物紫花地丁在抗糖尿病及防治相关代谢性疾病中的应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002032438A1 (fr) * 2000-09-13 2002-04-25 Jiangsu Kanion Pharmaceutical Co. Composition pharmaceutique traitant les maladies gynecologiques associees a la stase sanguine, les maladies cardio-vasculaires et cerebrales, les maladies respiratoires et autres maladies analogues
EP2491934A1 (en) * 2009-10-20 2012-08-29 Zuoguang Zhang Use of albiflorin for anti-depression

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HONG, E.-G. ET AL.: "A review of experimental study for herbal simplexes of anti-inflammatory effects since 2001", THE JOURNAL OF KOREAN MEDICAL OPHTHAL MOLOGY & OTOLARYNGOLOGY & DERMATOLOGY, vol. 25, no. 4, 2012, pages 12 - 34, XP055337559 *
LEE, J. K. ET AL.: "Screening of medicinal plants containing lipase inhibitor and optimal extraction conditions", KOREAN JOURNAL OF MEDICINAL CROP SCIENCE, vol. 20, no. 1, 2012, pages 1 - 7, XP053030766 *
See also references of EP3062807A4 *
SIDDIQI, H. S. ET AL.: "Studies on the antihypertensive and antidyslipidemic activities of Viola odorata leaves extract", LIPIDS IN HEALTH AND DISEASE, vol. 11, no. 6, 2012, pages 1 - 12, XP021130833 *

Also Published As

Publication number Publication date
KR20150050391A (ko) 2015-05-11
KR101672274B1 (ko) 2016-11-04
EP3062807A4 (en) 2017-06-14
CN105916514A (zh) 2016-08-31
EP3062807A1 (en) 2016-09-07

Similar Documents

Publication Publication Date Title
WO2012050396A2 (ko) 생약 추출물을 포함하는 간암 예방 또는 치료용 약학적 조성물
WO2010087577A2 (ko) 스페니쉬 오레가노 추출물, 여름세이보리 추출물 또는 카바크롤의 대사성 질환 치료를 위한 용도
WO2014171781A1 (en) Composition for preventing or treating hangover
WO2015064975A1 (en) Compositions comprising a viola herba extract, or an extract of viola herba, persicae semen, cinnamomi ramulus, and glycyrrhiza spp. for the prevention or treatment of lipid-related cardiovascular diseases and obesity
WO2018174448A1 (ko) 백출, 상심자, 구기자, 용안육, 우슬, 두충 및 천문동의 조합생약 추출물을 유효성분으로 함유하는 갱년기증후군의 치료 및 예방을 위한 조성물 및 이의 용도
WO2012050398A2 (ko) 생약 추출물을 포함하는 폐암 예방 또는 치료용 약학적 조성물
WO2016032249A1 (ko) 모새나무 추출물 또는 이의 분획물을 유효성분으로 포함하는 신경염증 또는 퇴행성 뇌신경 질환의 예방 또는 치료용 약학적 조성물
WO2020218720A1 (ko) 익모초 추출물 또는 레오누린을 함유하는 근육 질환 예방 또는 치료용 또는 근 기능 개선용 조성물
WO2015111832A1 (ko) 지실 추출물을 포함하는 전립선 관련 질환의 예방 또는 치료용 조성물
WO2020067748A1 (en) Composition having anti-stress, anti-depressant or anxiolytic effect comprising at least one compound selected from the group consisting of undecanal, dodecanal, and pharmaceutically acceptable salts thereof as active ingredient
WO2019231150A1 (ko) 해국 추출물을 포함하는 근육 질환 예방, 개선 또는 치료용, 또는 근 기능 개선용 조성물
WO2015030336A1 (ko) 포도 및 오미자 복합 추출물을 포함하는 대사증후군 관련 질환의 예방 또는 치료용 조성물
KR102519649B1 (ko) 캠퍼롤 및 에피카테킨 갈레이드를 포함하는 홍경천 추출물을 포함하는 전립선 관련 질환의 예방 또는 치료용 조성물
WO2012115469A2 (ko) 항염증성의 경구 투여용 기능성 식품 조성물 및 상기 기능성 식품 조성물의 제조방법
WO2016093613A2 (ko) 진피 추출물을 포함하는 이상 체중 감소 증상의 예방 또는 치료용 조성물
WO2013012117A1 (en) Pharmaceutical compositions for preventing or treating inflammatory diseases, comprising phytosterol compound
WO2016129902A1 (ko) 번아웃증후군의 예방, 개선 또는 치료용 조성물
WO2017030419A1 (ko) 애기땅빈대 추출물 또는 분획물을 유효성분으로 포함하는 비만의 예방 또는 치료용 조성물
WO2020204479A1 (ko) 포도잎 추출물 및 병풀 추출물을 포함하는 정맥순환 장애 개선용 조성물
KR20140114950A (ko) 백두구 추출물을 포함하는 항비만 조성물
WO2019231198A1 (ko) 승마 추출물, 이의 분획물 또는 승마에서 유래된 화합물을 유효성분으로 포함하는 퇴행성 뇌질환의 예방 또는 치료용 조성물
WO2019198982A1 (ko) 구꼬아민 a 및 구꼬아민 b를 유효성분으로 함유하는 골격근 위축 예방 또는 개선용 조성물
WO2019088381A1 (ko) 도화 및 하엽 복합 추출물을 포함하는 비만 및 대사성 질환의 예방, 개선 또는 치료용 조성물
WO2020004989A1 (ko) 김치를 포함하는 악액질 예방, 개선 또는 치료용 조성물
WO2015105373A1 (ko) 화살나무 추출물 또는 이의 분획물을 포함하는 천식의 예방 또는 치료용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14858980

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2014858980

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2014858980

Country of ref document: EP